Press Room

Webinar - Analytical Quality by Design Road Map

Start
Wednesday, March 15, 2017 - 14:00
End
Wednesday, March 15, 2017 - 17:00
Location: online
Analytical Quality by Design QbD | Hovione

 

 
Speakers
António Ramos - Analytical Chemist
Lúcia Volta e Sousa - PhD Student / Analytical Chemist

There is a current trend in pharmaceutical industry on applying Analytical Quality by Design (AQbD) to method development as a part of analytical method lifecycle. Indeed, there is a considerable interest in enhancing method understanding in order to reduce failures, increase method robustness and reliability through its lifecycle. Reversed Phase-Liquid Chromatography (RP-LC) is the widest technology used in any pharmaceutical analysis so its performance should be widely studied during method development in order to ensure its robustness throughout the entire lifecycle. So, the application of an AQbD approach through a RP-LC method development represents an excellent opportunity to enhance method development activities while turn time into knowledge.

At Hovione, new analytical stepwise methodology based on QbD principles, already used at Hovione for process development, is being developed and has been applied to RP-LC methods development. This involves several steps: from objectives pre-definition; followed by the selection of an appropriate technology; passing through a method understanding process of how potential sources of variability may affect method performance, through structured and scientific-based tools (ex: DoE);  and ends up with a risk mitigation phase, where all sources of variability are reduced and controlled based on method understanding. So, in order for you to understand Hovione's point of view for AQbD application, I invite you to assist this exciting webinar where is presented some case studies in RP-LC, that highlights the application of this new methodology, as well as the newly defined of important AQbD concepts, such as Analytical Target Profile, Method Operable Design Region, Normal Operable Range and Analytical Control Strategy.

Key Learning Objectives:

  • Application of QbD principles to reverse-phase liquid chromatography methods
  • Development strategy to obtained increased reliability and robustness over method's lifecycle
  • Evaluating the relevant QbD elements and establishing their combined performance to reduce failures and costs over method lifecycle

Join Hovione's Webinar NOW!

Time Option 1 Time Option 2
register-now
2:00 pm (GMT)

10:00 am (EST)
4:00 pm (GMT)

9:00 am (PST)

12:00 pm (EST)

 

 

 

 

 

 

You might be also interested in:

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026